Nucleotide sequences of human immunodeficiency virus type 2 (HIV-2), probes of HIV-2, and methods of using these probes
AssigneeInstitut Pasteur
InventorsMarc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
Life of this patent
Estimating the term…
Abstract
A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
Claims21
A purified nucleic acid encoding a peptide comprising an amino acid sequence of either of the following formulas:
- XR--A-E-D-YL-DQ--L--WGC-----CZ
- or
- XA-E-D-YL-DZ,
- wherein X and Z are OH or NH.sub.2 or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens corresponds to an aminoacyl residue chosen from among those which permit the conservation of the immunological properties of either of the following peptide sequences:
- RVTAIEKYLQDQARLNSWGCAFRQVC
- or
- AIEKYLQDQ.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of either of the following formulas:
- X--E--Q-QQEKN--EL--L---Z
- or
- XQ-QQEKNZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of either of the following peptide sequences:
- SLEQAQIQQEKNMYELQKLNSW
- or
- QIQQEKN.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of either of the following formulas:
- XEL--YK-V-I-P-G-APTK-KR-----Z
- or
- XYK-V-I-P-G-APTK-KRZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of either of the following peptide sequences:
- ELGDYKLVEITPIGFAPTKEKRYSSAH
- or
- YKLVEITPIGFAPTKEK.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of either of the following formulas:
- X----VTV-YGVP-WK-AT--LPCA-Z
- or
- XVTV-YGVP-WK-ATZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- CTQYVTVFYGVPTWKNATIPLFCAT,
- VTVFYGVPTWKNAT,
- EKLWVTVYYGVPVWKEATTTLFCAS,
- or
- VTVYYGVPVWKEAT.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of either of the following formulas:
- X---QE--L-NVTE-F--W-NZ
- or
- XL-NVTE-FZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- DDYQEITL-NVTEAFDAWNN,
- L-NVTE,
- PNPQEVVLVNVTENFNMWKN,
- or
- LVNVTE.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of one of the following formulas:
- XL---S-KPCVKLTPLCV--KZ,
- XKPCVKLTPLCVZ,
- or
- XS-KPCVKLTPLCVZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- ETSIKPCVKLTPLCVAMK,
- DQSLKPCVKLTPLCVSLK,
- KPCVKLTPLCV,
- or
- SLKPCVKLTPLCV.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of one of the following formulas:
- X---N-S-IT--C-Z
- or
- XN-S-ITZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- NHCNTSVITESCD,
- NTSVIT,
- TSCNTSVITQACP,
- or
- NTSAIT.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of the following formula:
- XYC-P-G-A-L-C-N-TZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of either of the following peptide sequences:
- YCAPPGYALLRC-NDT
- or
- YCAPAGFAILKCNNKT.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of the following formula:
- X----A-C------W--Z,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- NKRPRQAWCWFKG-KWKD
- or
- N--MRQAHCNISRAKWNA.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of one of the following formulas:
- X-G-DPE------NC-GEF-YCN-----NZ
- or
- XNC-GEF-YCNZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- KGSDPEVAYMWTNCRGEFLYCNMTWFLN,
- NCRGEFLYCN,
- -GGDPEIVTHSFNCGGEFFYCNSTQLFN,
- or
- NCGGEFFYCN.
A purified nucleic acid encoding a peptide comprising an amino acid sequence of one of the following formulas:
- X-----C-IKQ-I------G---YZ
- or
- XC-IKQ-IZ,
- wherein X and Z are OH or NH.sub.2, or at least one of X and Z comprises a terminal group comprising from one to five amino acid residues, provided that the immunological properties of the peptide having the terminal group shall not be essentially modified from the peptide lacking the terminal group, and wherein each of the hyphens correspond to an aminoacyl residue chosen from those which permit the conservation of the immunological properties of one of the following peptide sequences:
- RNYAPCHIKQIINTWHKVGRNVY,
- CHIKQII,
- TITLPCRIKQFINMWQEVGKAMY,
- or
- CRIKQFI.
A purified nucleic acid encoding a peptide, gag1, having the following formula:
- XNCKLVLKGLGMNPTLEEMLTAZ, in which X and Z are OH or NH.sub.2 or, to the extent that the immunological properties of the natural peptides lacking these groups shall not be essentially modified, the groups having from one to five amino acid residues, and each of the hyphens corresponding to an aminoacyl residue chosen from those which permit the conservation for the peptide characterized above of the immunological properties of the following peptide sequence:
- XNCKLVLKGLGMNPTLEEMLTAZ.
A method for detecting the presence or absence of Human Immunodeficiency Virus Type 2 (HIV-2) comprising:
- (1) contacting a sample suspected of containing viral genetic material of HIV-2 with at least one nucleotide probe, and
- (2) detecting hybridization between the nucleotide probe and the viral genetic material in the sample,
- wherein said nucleotide probe is complementary to the full-length sequence of the purified nucleic acid selected from the group consisting of the purified nucleic acids of claims 84-103.
Dependencies are inferred from the claim text.